Crossmark

PCSK9 inhibitors for treating familial hypercholesterolaemia

Crossref DOI link: https://doi.org/10.1038/nrendo.2014.205

Published Online: 2014-11-18

Published Print: 2015-01

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Mabuchi, Hiroshi

Nohara, Atsushi
License Information

Text and Data Mining valid from 2014-11-18
More Information

Article History

First Online: 18 November 2014

Competing interests

: H.M. and A.N. have received research grant funding from Aegerion, Astellas Pharma, AstraZeneca, Biopharm of Japan, Kowa, MSD, Sanofi, Shionogi and Takeda. H.M. has received an honoraria from AstraZeneca for an invited talk. A.N. has provided consulting to and is an advisory board member for Sanofi.